NCCN Task Force Report: Oral chemotherapy Journal Article
| Authors: | Weingart, S. N.; Brown, E.; Bach, P. B.; Eng, K.; Johnson, S. A.; Kuzel, T. M.; Langbaum, T. S.; Leedy, R. D.; Muller, R. J.; Newcomer, L. N.; O'Brien, S.; Reinke, D.; Rubino, M.; Saltz, L.; Walters, R. S. |
| Article Title: | NCCN Task Force Report: Oral chemotherapy |
| Abstract: | Oral chemotherapy is emerging as a new option for well-selected patients who can manage potentially complex oral regimens and self-monitor for potential complications. If a choice between oral and parenteral therapy is available, patients may opt for oral chemotherapy because it is more convenient to administer, allows them to avoid multiple office visits, and gives them a sense of control over their own cancer care. Whether these potential advantages are maintained in regimens that combine oral and parenteral drugs is less clear. The use of oral chemotherapeutic agents profoundly affects all aspects of oncology, including creating significant safety and adherence issues, shifting some traditional roles and responsibilities of oncologists, nurses, and pharmacists to patients and caregivers. The financing of chemotherapy is also affected. To address these issues, the NCCN convened a multidisciplinary task force consisting of oncologists, nurses, pharmacists, and payor representatives to discuss the impact of the increasing use of oral chemotherapy. © Journal of the National Comprehensive Cancer Network. |
| Keywords: | cancer chemotherapy; treatment outcome; lenalidomide; sorafenib; cytotoxic agent; erlotinib; fluorouracil; sunitinib; diarrhea; drug efficacy; drug safety; patient selection; unspecified side effect; capecitabine; cancer patient; methotrexate; topotecan; antineoplastic agent; anorexia; cancer palliative therapy; imatinib; multiple myeloma; vomiting; patient education; cyclophosphamide; continuous infusion; chronic myeloid leukemia; cetuximab; docetaxel; panitumumab; protein tyrosine kinase inhibitor; fever; rash; drug cost; patient care; gefitinib; etanercept; vorinostat; patient compliance; serotonin antagonist; erythema; caregiver; drug monitoring; nilotinib; patient counseling; lapatinib; chlorambucil; cost benefit analysis; epidermal growth factor receptor kinase inhibitor; mouth pain; mercaptopurine; swelling; nurse; oral chemotherapy; pharmacist; infliximab; cancer care; health care financing; chemotherapy administration; coverage and reimbursement; nccn task force report; parenteral chemotherapy; patient adherence; foot pain; hospital pharmacy; self monitoring |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 6 |
| Issue: | SUPPL. 3 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2008-03-01 |
| Start Page: | S1 |
| End Page: | S14 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 18377852 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 32" - "Export Date: 17 November 2011" - "Source: Scopus" |
Citation Impact
Related MSK Work